Data evolution: next era biological data hurdles for data storage, preservation and integrity
Date
2016-06-02
Authors
Slayden, Richard, author
Journal Title
Journal ISSN
Volume Title
Abstract
Description
Presented at the National data integrity conference: data sharing: the how, why, when and when not to share held on June 2-3, 2016 at University of Colorado, Denver, Colorado. The National Data Integrity Conference is a gathering of people sharing new challenges and solutions regarding research data and integrity. This conference aims to provide attendees with both an understanding of data integrity issues and impart practical tools and skills to deal with them. Topics addressed will include data privacy, openness, policy, education and the impacts of sharing data, how to do it, when to do it, and when not to. Speakers and audience members come from diverse fields such as: Academic Research; Information Technology; Quality Assurance; Regulatory Compliance; Private Industry; Grant Funding; Government.
Quality Central: sharpening the focus on sound science and quality practices
Dr. Richard Slayden has expertise in all stages of academic drug development ranging from basic bacterial physiology, target discovery and validation to development of drug delivery formulations and efficacy testing in animal models. He has been involved in M. tuberculosis research since 1993 and F. tularensis, B. pseudomallei and Y. pestis research since 2005. Uniquely, his work includes a wide variety of integrative research strategies that affords for a complete investigation of rug mode of action and bacterial metabolism and response in vivo. Specifically, his research team has experience indentifying clinically relevant drug targets, assessing protein function via gene dosage [knockout & knockdown mutants, dominant negative and merodiploid strains], determining mode of action, and advanced lead compound formulation development. Importantly, these strategies were developed to manipulate essential molecular targets and to exploit them for the development of novel broad-spectrum chemotherapies with potency against priority pathogens and medically important difficult to treat bacterial pathogens.
PowerPoint presentation given on June 2, 2016.
Quality Central: sharpening the focus on sound science and quality practices
Dr. Richard Slayden has expertise in all stages of academic drug development ranging from basic bacterial physiology, target discovery and validation to development of drug delivery formulations and efficacy testing in animal models. He has been involved in M. tuberculosis research since 1993 and F. tularensis, B. pseudomallei and Y. pestis research since 2005. Uniquely, his work includes a wide variety of integrative research strategies that affords for a complete investigation of rug mode of action and bacterial metabolism and response in vivo. Specifically, his research team has experience indentifying clinically relevant drug targets, assessing protein function via gene dosage [knockout & knockdown mutants, dominant negative and merodiploid strains], determining mode of action, and advanced lead compound formulation development. Importantly, these strategies were developed to manipulate essential molecular targets and to exploit them for the development of novel broad-spectrum chemotherapies with potency against priority pathogens and medically important difficult to treat bacterial pathogens.
PowerPoint presentation given on June 2, 2016.
Rights Access
Subject
storage
preservation
integrity
data set